How We Work
-
01
Find
We identify and select innovations which fit our therapeutic interests, expertise and strategic model.
-
02
Focus
We devote intellectual and financial resources to deliver a risk-balanced pipeline of projects that are investor and industry ready.
-
03
Transform
Starting with the end in mind, we collaborate with world-leading innovators to enhance and accelerate the translation of great science into effective treatments.
-
04
Grow
Our strategy includes building a portfolio of independent entities with a common support framework and a shared vision. Dynamic joint ventures and end-focused partnerships will progress each entity to commercialisation and deliver maximum value.
Four Compelling Reasons to Choose ValiRx
Patent-Protected Technology
ValiRx's lead CytoLytix cancer therapy secured a granted patent in May 2026, with a further patent update in August 2026, providing a strengthening IP foundation that protects the company's most advanced asset and its potential across multiple cancer types.
Active Commercial Pipeline
A series of commercial milestones, including a licensing agreement with Dominion Biotech, a collaboration with Voxcell BioInnovation, and regular Cytolytix and Inaphaea commercial updates, demonstrates a pipeline that is translating science into real commercial progress.
A Growing Portfolio of Entities
The formation of ValiRx Animal Health Ltd in March 2026, alongside active evaluation programmes including Stingray and University of Dundee, shows a disciplined strategy of building independent entities, each with its own pathway to value creation.
Investor-Backed Momentum
Two successful fundraises totalling over £2.2m, including an oversubscribed retail offer in May 2026, reflect continued investor confidence in ValiRx's strategy and the company's ability to attract capital at key stages of development.
Our Journey
-
2006/Founded
ValiRx Established
Established as a UK-based life sciences company with a mission to advance cutting-edge therapies in cancer and women's health.
-
Oct 2006/AIM Listing
Listed on London Stock Exchange
Listed on LSE AIM market as VAL, providing access to capital to accelerate drug development and pipeline growth.
-
Oct 2022/Portfolio Growth
Cytolytix Limited Formed
Established as an independent portfolio entity to advance CLX001, a selective cancer therapy initially targeting Triple Negative Breast Cancer.
-
Mar 2023/Research Infrastructure
Inaphaea BioLabs Established
Created a dedicated research entity to provide the scientific infrastructure and expertise to advance the therapeutic pipeline.
-
Aug 2025/Prostate Cancer
Blue Ribbon Bio Formed
Established as a wholly owned subsidiary to hold our prostate cancer assets, starting with the VAL201 intellectual property licensed from Cancer Research Horizons, as we build a focused prostate cancer portfolio.
-
Mar 2026/Veterinary Oncology
ValiRx Animal Health Formed
Incorporated as a wholly owned subsidiary to develop and commercialise our oncology assets for the veterinary market, with an initial focus on canine cancers including osteosarcoma, lymphoma and hemangiosarcoma.
-
2026/Today & Beyond
A Growing Pipeline
With VAL201, VAL301 and CLX001 in active development, ValiRx is building a diversified portfolio positioned for value creation across cancer and women's health.
Explore Our Research
Access analyst coverage and the scientific evidence behind our pipeline programmes.
View Analyst Research